SCHEMBL7599309

SCHEMBL7599309

CCN(CC)C(=O)C(c1ccccc1)C1CCN(c2ccc(NC(=O)C3CCCC3)cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY2R P49146 8/20 0.55
LMNA P02545 4/20 0.48
TP53 P04637 2/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MTTP P55157 1/20 0.48
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RAB9A P51151 1/20 0.43
KCNH2 Q12809 1/20 0.42
MCHR1 Q99705 1/20 0.42
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
GAA P10253 1/20 0.42
MALT1 Q9UDY8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7602855 0.88 NPY2R (0.69) NPY2RMTTP
SCHEMBL5131754 0.86 NPY2R (0.68) NPY2RMTTPKCNH2MCHR1
SCHEMBL7602264 0.81 NPY2R (0.80) NPY2RMAPTMTTPMEN1KMT2A
SCHEMBL5131784 0.81 NPY2R (0.48) NPY2RLMNAMAPTSMN1; SMN2MTTP
SCHEMBL7604114 0.79 NPY2R (0.80) NPY2RMAPTMTTPMEN1KMT2A
SCHEMBL7602208 0.77 NPY2R (0.82) NPY2RMAPTMTTPMEN1KMT2A
SCHEMBL1094893 0.72 PTPN1 (0.62) NPY2RTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL5079835 0.72 NPY2R (0.68) NPY2R
SCHEMBL14538115 0.71 NPY2R (1.00) NPY2RMAPTMTTPMEN1KMT2A
SCHEMBL7607035 0.71 NPY2R (1.00) NPY2RMAPTMTTPMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183239-B2 Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-05-22 US disclosed
US-8183239-B2 Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-05-22 US disclosed
US-20070100141-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed
US-20070100141-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100141-A1 SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NPY2R, NPY5R, NPY4R NPY2R 1/4885LMNA 3057/4885TP53 4846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.